Search
Florquinitau (18F)
go.drugbank.com/drugs/DB19215ApprovedFlorquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer. … [L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease
Tocainide
go.drugbank.com/drugs/DB01056ApprovedWithdrawnAn antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
PRG-A01
go.drugbank.com/drugs/DB18613InvestigationalPRG-A01 is a novel inhibitor of Cu, Zn-superoxide dismutase (SOD1) misfolding and aggregation.
Tribromsalan
go.drugbank.com/drugs/DB20138ApprovedWithdrawnTribromsalan is a small molecule drug. Tribromsalan has a monoisotopic molecular weight of 446.81 Da.
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnWhile it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.
Amibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. … It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels.
Manitimus
go.drugbank.com/drugs/DB06481InvestigationalFK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.
Bunamiodyl
go.drugbank.com/drugs/DB04814ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.
Dantron
go.drugbank.com/drugs/DB04816ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
International brands: Scatron DMixtures: Regulex D Cap